Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

NCT01423084 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease
Meningococcal Meningitis

Interventions

BIOLOGICAL: Serogroup B meningococcal vaccine

Sponsor

Novartis

Collaborators

[object Object]